To evaluate the in-vivo efficacy and safety of a skin care formulation in terms of reduction inhyperpigmentation, skin glow and skin radiance on healthy female subjects. - NI

Onesto Labs Pvt. Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•1.Indian female subjects.
•2.Healthy subjects
•3.Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….).
•4.Having hyperpigmentation (Acne PIH) dark spot

•Being pregnant or breastfeeding or having stopped to breastfeed in the past three months.
•Having refused to give her assent by signing the consent form.
•Taking part in another study liable to interfere with this study.
•Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area.
•Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less
•than 6 months).
•Having a progressive asthma (either under treatment or last fit in the last 2 years).
•Being epileptic.
•Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6
•Having cutaneous hypersensitivity
•Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic
•products or food products or to latex
•Having known allergy to any of the Ingredient of the Test Product.
•Following a chronic medicinal treatment comprising any of the following products: aspirin-based
•products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes
•(the only medication permitted is paracetamol)
•Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6

发起方

Onesto Labs Pvt. Ltd.